Vascular Investigation and Therapy最新文献

{"title":"Effectiveness of drug-coated balloon in treating real-world femoropopliteal lesions: A cohort study","authors":"Guo-chen Niu, Bihui Zhang, Ziguang Yan, Yinghua Zou, Xiao-qiang Tong, Min Yang","doi":"10.4103/2589-9686.379843","DOIUrl":"https://doi.org/10.4103/2589-9686.379843","url":null,"abstract":"BACKGROUND: The drug-coated balloon is superior to angioplasty for simple femoropopliteal lesions in clinical trials. The evidence on the effectiveness of Acotec drug-coated balloon in treating complex femoropopliteal lesions in the real world is limited. This study aimed to investigate the clinical effectiveness of Acotec drug-coated balloon in real-world femoropopliteal lesions. METHODS: The retrospective study enrolled 128 limbs of 120 patients treated with the Acotec drug-coated balloon in femoropopliteal lesions. Patency rate, target lesion revascularization (TLR) rate, clinical improvement, and safety endpoints of femoropopliteal lesions were analyzed for a 12-month follow-up. Risk factors of primary patency and freedom from TLR were identified. RESULTS: Of the limbs, 31.2% had chronic limb-threatening ischemia. The mean lesion length was 199.3 ± 108.9 mm, and 75.8% were occlusions. Kaplan–Meier estimates of 12-month primary patency were 88.5%, whereas freedom from TLR rate was 95.2%. Rutherford category improved in 87.1% of patients. Freedom from 30-day major adverse limb events was 95.5%. The 12-month overall mortality was 8.6%. No independent risk factors for restenosis and TLR were identified. CONCLUSIONS: The results suggest that Acotec drug-coated balloon is safe and effective in treating complex femoropopliteal artery diseases in the real world.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"31 1","pages":"38 - 44"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77323456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open surgical repair of common femoral artery aneurysm: Case report and literature review","authors":"Kristine S. Kwan, Hai-Lei Li, Y. Chan, D. Cui, S. Cheng","doi":"10.4103/2589-9686.377615","DOIUrl":"https://doi.org/10.4103/2589-9686.377615","url":null,"abstract":"Common femoral artery (CFA) aneurysms are rare with an unknown exact incidence and often found in elderly males with chronic diseases. Early recommendations are to repair aneurysms with a maximum diameter of ≥2.5cm. We present the case of a 37-year-old male with a right CFA aneurysm. Open surgical repair (OSR) consisting of aneurysmectomy and reconstruction of the femoral artery with a bifurcated prosthetic graft was applied. Our study details this case and thoroughly reviews on the treatment of femoral artery aneurysms in the literature. OSR and vascular reconstruction with interposition prosthetic graft were durable and associated with favorable outcomes.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"48 1","pages":"16 - 19"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85366153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The point on calf vein thrombosis","authors":"P. Antignani","doi":"10.4103/2589-9686.377614","DOIUrl":"https://doi.org/10.4103/2589-9686.377614","url":null,"abstract":"","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"21 1","pages":"1 - 5"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79002118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular treatment of the subclavian artery pseudoaneurysm: Two case reports","authors":"Hao Cai, Yunfeng Pang, Ziqiang Sun, Song Jin","doi":"10.4103/2589-9686.377611","DOIUrl":"https://doi.org/10.4103/2589-9686.377611","url":null,"abstract":"Endovascular treatment is widely used for treating the subclavian artery pseudoaneurysm (SAP) because of its small trauma, fast recovery, exact effect, and low incidence of complications. However, when the systemic disease or infection that causes SAP is in the active phase, treatment of the primary disease is more critical. Surgical intervention should be performed after systemic symptoms have been controlled unless the situation is particularly critical. We introduced two cases of SAP caused by brucellosis and Behcet's disease and discussed the course of treatment.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"51 1","pages":"20 - 24"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73595322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large distal tear of aortic dissection: Risk factor for postoperative distal aortic segmental enlargement","authors":"Lizhi Lv, Yan-qing Chen, Yu Shen, Zaiping Jing, Yi Shi, Simeng Zhang, Q. Lu","doi":"10.4103/2589-9686.377613","DOIUrl":"https://doi.org/10.4103/2589-9686.377613","url":null,"abstract":"BACKGROUND: The traditional treatment for aortic dissections (ADs) is a proximal repair of AD, but the long-term prognosis of residual distal dissection is unsatisfactory. The distal aortic intimal tear of distal aortic segmental enlargement (DASE) is evaluated via its size, with risk assessment, and assessed its risk, which will provide clinicians with diagnosis and treatment direction. METHODS: We analyzed 419 ADs patients who underwent radiographic examination of the aorta between September 1999 and May 2014. We recorded the area of the aortic intimal tear and divided it into two groups (75 patients in DASE group and 344 patients in non-DASE group). Logistics regression analysis or natural logarithm transformation was used to explore the potential risk of remaining distal tears to DASE, while the Logistic multiple regress equations were used to find out the independent risk factors. RESULTS: The postoperative large tear was defined as short diameter ≥5.0 mm. The independent risk factors of DASE are as follows: Short diameter of postoperative tears (odds ratios [ORs], 1.10;95% confidence interval [CI], 1.02–1.19; P < 0.0120); short diameter of the first tear after operation (OR, 1.12; 95% CI, 1.00–1.26; P < 0.0580) and the existence of large tears (OR, 1.13; 95% CI, 1.01–1.26; P < 0.0298). CONCLUSIONS: Our findings suggest that the size of the remaining tears and the existence of large tears are the key risk factors for patients with DASE. Patients with large remaining tears should be supervised regularly and treated timely.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"96 3 1","pages":"11 - 15"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87691743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of mechanical properties of the stent's outflow segment during thoracic endovascular aortic repair","authors":"Yu Shen, Zheng Chen, Q. Lu","doi":"10.4103/2589-9686.377612","DOIUrl":"https://doi.org/10.4103/2589-9686.377612","url":null,"abstract":"AIMS AND OBJECTIVES: To discuss the mechanical properties of stents and optimize the stents' selection scheme of overlapping segment through in vitro mechanical simulation of stent grafts. MATERIALS AND METHODS: The radial force tester was used to measure the radial force of different aortic covered stents, bare stents and the combination of the two. Linear relationship between the radial force at the distal end of the stent and oversize rate was plotted. The stent-induced aortic wall shear stress was evaluated intuitively by mechanical simulation. RESULTS: The radial force curve of the distal end of the thoracic aortic covered stent reflected the superelastic characteristics of aortic stent, and the characteristics was more obvious in stents composed of nickel-titanium than stainless; When different size of Hercules stents were combined with the same sized restrictive bare stent, the oversize rate of overlapping segment was the same, and the radial force was similar; At the initial compression diameter, the use of restrictive bare stent can improve the chronic outward force, but at high compression level, the chronic outward force of the overlapping segment was higher than that of the individual aortic covered stent. CONCLUSIONS: Based on in vitro mechanical simulation, the stent-vessel wall interaction after implantation can be more intuitively understood. The application of restrictive bare stents can change the radial force of the overlapping segment of the stents by reducing the oversize rate of the distal end of the stent-graft, but it can be harmful at a higher compression level.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"64 1","pages":"6 - 10"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90315957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of RAGE, MAPK and NF-κB pathway in the advanced glycation end-products induced HUVECs dysfunction","authors":"Xun Wang, Yisui Wang, Q. Zeng, Chenyang Qiu, Yangyan He, Zi-heng Wu, Yun-jun He, T. Shang, Hong-kun Zhang, Qianqian Zhu, Dong-lin Li","doi":"10.4103/2589-9686.360874","DOIUrl":"https://doi.org/10.4103/2589-9686.360874","url":null,"abstract":"OBJECTIVE: The objective of this study was to investigate how receptor for advanced glycation end-products–mitogen-activated protein kinase–nuclear factor-kappa B (MAPK-NF-κB) pathway is involved in advanced glycation end-product (AGE)-induced human umbilical venous endothelial cell (HUVEC) dysfunction. MATERIALS AND METHODS: HUVECs were cultured with AGEs, anti-RAGE, inhibitors of MAPK or NF-κB respectively. Then we detected endothelial nitric oxide synthase (eNOS) activation, nitric oxide (NO) concentration, cell migration ability, and RAGE expression of HUVECs. RESULTS: AGEs depressed eNOS activation, decreased NO concentration, impaired endothelial cell (EC) migration, and upregulated RAGE expression, which could be recovered by p38 inhibitor and extracellular regulated protein kinases (ERK) inhibitor. However, these effects could not be recovered by NF-κB inhibitor. CONCLUSIONS: AGEs increase RAGE expression and decrease NO release and migration of HUVECs through RAGE-MAPK pathway, but not NF-κB pathway.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"65 1","pages":"80 - 87"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78080851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of occlusive devices in endovascular repair of Stanford type B aortic dissection with insufficient landing zones","authors":"Zi-lun Li, Rui Wang, Mian Wang, Chenshu Liu, R. Wu, C. Yao, G. Chang","doi":"10.4103/2589-9686.360873","DOIUrl":"https://doi.org/10.4103/2589-9686.360873","url":null,"abstract":"OBJECTIVES: Occlusion of intimal tear with occlusive devices is an alternative or adjuvant method for endovascular repair of Stanford type B aortic dissection (TBAD) with insufficient landing zones. This study aimed to evaluate the efficacy and safety of using occluders in highly selective TBAD patients inappropriate for conventional thoracic endovascular aortic repair (TEVAR). METHODS: All patients undergoing TEVAR between July 2009 and July 2015 were retrospectively reviewed and patients treated with only or adjuvant occlusive devices were included in the study. Demographic data, clinical characteristics, perioperative data, and follow-up were collected and analyzed. RESULTS: A total of 10 TBAD patients treated with occluders were included in the study. The mean age was 56.8 ± 12.7 years old and the majority of the patients were male (7/10). Only occluders were applied to seal the proximal tears in seven cases, while occluders combined with other endovascular techniques were used in three cases. No 30-day mortality operative reintervention was required in two cases. Eight patients were followed up for 10.0 ± 4.1 years and two cases were lost to follow-up. Three patients died during the follow-up period; one patient died of stroke, while the other two patients died due to noncardiovascular causes. One reintervention was performed due to endoleak 2 years after the surgery. CONCLUSIONS: The early and long-term outcomes of the 10 patients show that treating difficult aortic lesions unfit for traditional TEVAR with occluders is effective and safe. The technique may provide a treatment alternative in highly selective TBAD patients unfit for traditional TEVAR.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"188 1","pages":"75 - 79"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76949356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical study of hepatocyte growth factor in the treatment of diabetic lower limb arteriosclerosis obliterans","authors":"Ling Zhang, Zhixiang Su, Yongquan Gu, S. Cui, Lianrui Guo, Jian-ming Guo","doi":"10.4103/2589-9686.360871","DOIUrl":"https://doi.org/10.4103/2589-9686.360871","url":null,"abstract":"OBJECTIVE: The objective of this study was to investigate the safety and efficacy of hepatocyte growth factor (HGF) gene therapy in the patients with diabetic lower limb arteriosclerosis obliterans, provide theoretical support for better coordination of clinical operation and anesthesia, ensure medical safety, and improve the quality of nursing. MATERIALS AND METHODS: Twenty-one patients with Grade 4–6 (Rutherford classification) and limb ischemia who met the inclusion criteria were divided into four dose groups, including three cases in the 4 mg group, six cases in the 8 mg group, five cases in the 12 mg group, and seven cases in the 16 mg group. The dosage of each group was divided into equal doses, which were injected intramuscularly on the 1st and 15th days of treatment, respectively. The dosage of each injection point was 0.25 mg/0.5 ml. Adverse reactions, visual analog scale (VAS) scores for pain and ulcer healing were observed on the 1st, 8th, 15th, 21st, 28th, 59th, and 91st days after the treatment. The ankle-brachial index (ABI) was measured on the 1st, 28th, 59th, and 91st days after the treatment. RESULTS: Complications, serious adverse reactions, and abnormal test results did not occur in the patients during the operation. After the operation, the pain had significantly reduced in 17 cases, the average VAS score of all cases decreased from 5.95 to 1.64 (P < 0.05), and the pain disappeared completely in four cases. The average ABI of all cases increased from 0.49 to 0.63 (P < 0.05), five cases had ulcer, and four cases had gangrene. After treatment, one case of ulcer and one case of gangrene healed completely, and three cases of ulcer and one case of gangrene improved significantly, and one case of ulcer and two cases of gangrene had no significant change. CONCLUSION: HGF gene therapy can effectively treat diabetic lower limb arteriosclerosis obliterans, relieve the clinical symptoms and improve the quality of life. The smooth operation is inseparable from the cooperation of nurses, including careful preoperative visit, strict aseptic operation during the operation, follow-up visit regularly after the operation, and mastering the changes in patients' condition in the whole process to provide high-quality nursing for patients.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"77 1","pages":"88 - 90"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91364474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial claudication","authors":"P. Abraham, Simon Lecoq, J. Hersant, S. Henni","doi":"10.4103/2589-9686.360872","DOIUrl":"https://doi.org/10.4103/2589-9686.360872","url":null,"abstract":"Arterial claudication is generally the revealing form of clinically symptomatic lower extremity artery disease. It is defined as a pain of limb muscles that occurs during exercise and is relieved within 10 min when exercise is lowered or stopped. Atherosclerosis is the first underlying cause of arterial intermittent claudication. As such, the occurrence of arterial claudication is a severe medical event sharing almost similar the long-term morbidity and mortality risk as other arterial events such as stroke or myocardial infarction. Comorbid (both vascular and nonvascular) affections must be actively searched. Surgery is generally indicated only when medical treatment and training have failed to improve symptoms. This paper shortly reviews the cause, presentation, diagnostic algorithm, and treatments of arterial claudication.","PeriodicalId":34849,"journal":{"name":"Vascular Investigation and Therapy","volume":"14 1","pages":"68 - 74"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88776421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}